tetano
Editor, Senior Moderator
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59? adjuvant
Vaccine now in large scale production highlighting rapid response capability of novel FDA licensed cell culture technology
135 confirmed cases and 45 deaths from H7N9 virus since emergence in March according to the World Health Organization[1]
Basel, Switzerland, November 14, 2013 - Novartis announced today interim results from a Phase 1 clinical trial with its proprietary cell culture vaccine for the H7N9 avian influenza virus involving 400 healthy volunteers (18-64 years of age). The data shows 85% of subjects achieved a protective immune response after two doses of the 15 ug MF59 adjuvanted vaccine. Only 6% of subjects achieved a protective response when given two doses of the 15ug un-adjuvanted vaccine. The full data set from the trial will be submitted to a peer-reviewed journal for publication in the near future.
The vaccine was produced utilizing full-scale cell-culture manufacturing technology, an alternative technology that can significantly accelerate vaccine production versus traditional egg-based methods.[2] Cell-culture technology utilizes a well-characterized mammalian cell line rather than chicken eggs to grow virus strains.[3]
...
http://www.novartis.com/newsroom/media-releases/en/2013/1743124.shtml
Vaccine now in large scale production highlighting rapid response capability of novel FDA licensed cell culture technology
135 confirmed cases and 45 deaths from H7N9 virus since emergence in March according to the World Health Organization[1]
Basel, Switzerland, November 14, 2013 - Novartis announced today interim results from a Phase 1 clinical trial with its proprietary cell culture vaccine for the H7N9 avian influenza virus involving 400 healthy volunteers (18-64 years of age). The data shows 85% of subjects achieved a protective immune response after two doses of the 15 ug MF59 adjuvanted vaccine. Only 6% of subjects achieved a protective response when given two doses of the 15ug un-adjuvanted vaccine. The full data set from the trial will be submitted to a peer-reviewed journal for publication in the near future.
The vaccine was produced utilizing full-scale cell-culture manufacturing technology, an alternative technology that can significantly accelerate vaccine production versus traditional egg-based methods.[2] Cell-culture technology utilizes a well-characterized mammalian cell line rather than chicken eggs to grow virus strains.[3]
...
http://www.novartis.com/newsroom/media-releases/en/2013/1743124.shtml